RU2004110055A - Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов - Google Patents
Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов Download PDFInfo
- Publication number
- RU2004110055A RU2004110055A RU2004110055/04A RU2004110055A RU2004110055A RU 2004110055 A RU2004110055 A RU 2004110055A RU 2004110055/04 A RU2004110055/04 A RU 2004110055/04A RU 2004110055 A RU2004110055 A RU 2004110055A RU 2004110055 A RU2004110055 A RU 2004110055A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- lower alkyl
- optionally substituted
- nch
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (21)
1. Соединение общей формулы 1
или его фармацевтически приемлемая соль, где
R1 представляет собой Н или CN,
R2 выбран из CH2R5, CH2CH2R5 и C(R3)(R4)-X2-(CH2)aR5,
R3 и R4, каждый независимо, выбраны из Н и Me;
R5 выбран из CON(R6)(R7), N(R8)C(=O)R9, N(R8)C(=S)R9, N(R8)SO2R10 и N(R8)R10;
R6 и R7, каждый независимо, представляют собой R11(CH2)b, или вместе они представляют собой -(CH2)2-Z-(CH2)2- или -СН2-о-С6Н4-Z-СН2-;
R8 представляет собой Н или Me;
R9 выбран из R11(CH2)b, R11(CH2)bO и N(R6)(R7);
R10 представляет собой R11(CH2)b;
R11 выбран из Н, алкила, возможно замещенного арила, возможно замещенного ароила, возможно замещенного арилсульфонила и возможно замещенного гетероарила;
R12 выбран из H2NCH(R13)CO, H2NCH(R14)CONHCH(R15)CO, C(R16)=C(R17)COR18 и R19OCO;
R13, R14 и R15 выбраны из боковых цепей белковых аминокислот;
R16 выбран из Н, низшего алкила(C1-C6) и фенила;
R17 выбран из Н и низшего алкила(C1-C6);
R18 выбран из Н, низшего алкила(C1-C6), ОН, группы O-(низший алкил (C1-C6)) и фенила;
R19 выбран из низшего алкила(C1-C6), возможно замещенного фенила и R20C(=O)OC(R21)(R22);
R20, R21 и R22, каждый независимо, выбраны из Н и низшего алкила(С1-С6);
Z выбран из ковалентной связи, -(СН2)с-, -O-, -SOd- и -N(R10)-;
X1 представляет собой S или СН2;
X2 представляет собой О, S или CH2;
а равно 1, 2 или 3;
b равно 0-3;
с равно 1 или 2 и
d равно 0-2.
2. Соединение по п.1, где R1 представляет собой Н.
3. Соединение по п.1, где R1 представляет собой CN.
4. Соединение по п.1, где R2 выбран из CH2CH2R5 и C(R3)(R4)-X2-(CH2)aR5.
5. Соединение по п.2, где X1 представляет собой СН2.
6. Соединение по п.1, где X1 представляет собой S.
7. Соединение по п.4, где R3 и R4 оба представляют собой Н, X2 представляет собой СН2, и а равно 1 или 2.
8. Соединение по п.7, где R2 выбран из CH2CH2CH2R5 и CH2CH2CH2CH2R5.
9. Соединение по п.1, где R5 представляет собой CON(R6)(R7).
10. Соединение по п.1, где R5 выбран из N(R8)C(=O)R9, N(R8)C(=S)R9, N(R8)SO2R10 и N(R8)R10.
11. Соединение по п.5, где R5 выбран из CON(R6)(R7), N(R8)C(=O)R9, N(R8)C(=S)R9 и N(R8)R10.
12. Соединение по п.1, где R12 выбран из H2NCH(R13)CO и H2NCH(R14)CONHCH(R15)CO.
13. Соединение по п.1, где R12 представляет собой R19OCO.
14. Фармацевтическая композиция, содержащая соединение по любому из пп.1-13.
15. Применение соединения по любому из пп.1-13 в качестве ингредиента в приготовлении фармацевтической композиции.
16. Способ лечения гипергликемии, при котором индивидууму, нуждающемуся в таком лечении, вводят эффективное количество соединения по любому из пп.1-13.
17. Соединение или фармацевтическая композиция по любому из пп.1-14, применение по п.15 или 21 или способ по любому из пп.16 или 18-20, при условии, что R19 не представляет собой трет-бутил.
18. Способ лечения заболевания или медицинского состояния у человека или животного, при котором индивидууму, нуждающемуся в таком лечении, вводят эффективное количество соединения общей формулы 1
или его фармацевтически приемлемой соли, где
R1 представляет собой Н или CN,
R2 выбран из CH2R5, CH2CH2R5 и C(R3)(R4)-X2-(CH2)aR5,
R3 и R4, каждый независимо, выбраны из Н и Me;
R5 выбран из CON(R6)(R7), N(R8)C(=O)R9, N(R8)C(=S)R9, N(R8)SO2R10 и N(R8)R10;
R6 и R7, каждый независимо, представляют собой R11(CH2)b, или вместе они представляют собой -(CH2)2-Z-(CH2)2- или -СН2-о-С6Н4-Z-СН2-;
R8 представляет собой Н или Me;
R9 выбран из R11(CH2)b, R11(CH2)bO и N(R6)(R7);
R10 представляет собой R11(CH2)b,
R11 выбран из Н, алкила, возможно замещенного арила, возможно замещенного ароила, возможно замещенного арилсульфонила и возможно замещенного гетероарила;
R12 выбран из H2NCH(R13)CO, H2NCH(R14)CONHCH(R15)CO, C(R16)=C(R17)COR18 и R19OCO;
R13, R14 и R15 выбраны из боковых цепей белковых аминокислот;
R16 выбран из Н, низшего алкила(C1-C6) и фенила;
R17 выбран из Н и низшего алкила(C1-C6);
R18 выбран из Н, низшего алкила(C1-C6), ОН, группы O-(низший алкил(С1-C6)) и фенила;
R19 выбран из низшего алкила(C1-C6), возможно замещенного фенила и R20C(=O)OC(R21)(R22);
R20, R21 и R22, каждый независимо, выбраны из Н и низшего алкила(C1-C6);
Z выбран из ковалентной связи, -(СН2)с-, -O-, -SOd- и -N(R10)-;
X1 представляет собой S или СН2;
X2 представляет собой О, S или СН2;
а равно 1, 2 или 3;
b равно 0-3;
с равно 1 или 2 и
d равно 0-2.
19. Способ по п.18, где заболевание или медицинское состояние представляет собой нарушенную толерантность к глюкозе, диабет типа II или гипергликемию.
20. Способ по п.18, где заболевание или медицинское состояние является следствием процесса, опосредованного дипептидилпептидазой IV (DP-IV).
21. Применение соединения по любому из пп.1-13 в качестве ингибитора дипептидилпептидазы IV (DP-IV) или в качестве пролекарства ингибитора DP-IV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0125446.5A GB0125446D0 (en) | 2001-10-23 | 2001-10-23 | Novel anti-diabetic agents |
GB0125446.5 | 2001-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2004110055A true RU2004110055A (ru) | 2005-10-20 |
Family
ID=9924376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004110055/04A RU2004110055A (ru) | 2001-10-23 | 2002-10-23 | Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов |
Country Status (18)
Country | Link |
---|---|
US (1) | US7144886B2 (ru) |
EP (1) | EP1450794A1 (ru) |
JP (1) | JP2005510499A (ru) |
KR (1) | KR20040049321A (ru) |
CN (1) | CN1329375C (ru) |
AR (1) | AR037247A1 (ru) |
CA (1) | CA2464256A1 (ru) |
GB (1) | GB0125446D0 (ru) |
HU (1) | HUP0402403A3 (ru) |
IL (1) | IL161192A0 (ru) |
MX (1) | MXPA04003828A (ru) |
NO (1) | NO20042114L (ru) |
NZ (1) | NZ532044A (ru) |
PL (1) | PL370149A1 (ru) |
RU (1) | RU2004110055A (ru) |
UY (1) | UY27511A1 (ru) |
WO (1) | WO2003035067A1 (ru) |
ZA (1) | ZA200402500B (ru) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1399420B1 (en) | 2001-06-27 | 2007-12-05 | SmithKline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
US20040229848A1 (en) * | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
DE10348044A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
EP2289498A1 (en) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Use of inhibitors of glutaminyl clyclase |
DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR20150028829A (ko) | 2003-11-17 | 2015-03-16 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
ZA200708179B (en) | 2005-04-22 | 2009-12-30 | Alantos Pharmaceuticals Holding Inc | Dipeptidyl peptidase-IV inhibitors |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
JP2009504599A (ja) * | 2005-08-11 | 2009-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | Dpp−iv阻害剤を含有する医薬組成物 |
DK1942898T4 (da) | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
KR101281962B1 (ko) * | 2006-04-11 | 2013-07-08 | 아레나 파마슈티칼스, 인크. | 특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 gpr119 수용체를 사용하는 방법 |
JP2009533393A (ja) | 2006-04-12 | 2009-09-17 | プロビオドルグ エージー | 酵素阻害薬 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
-
2001
- 2001-10-23 GB GBGB0125446.5A patent/GB0125446D0/en not_active Ceased
-
2002
- 2002-10-22 UY UY27511A patent/UY27511A1/es not_active Application Discontinuation
- 2002-10-22 AR ARP020103995A patent/AR037247A1/es unknown
- 2002-10-23 JP JP2003537634A patent/JP2005510499A/ja not_active Withdrawn
- 2002-10-23 CN CNB028208544A patent/CN1329375C/zh not_active Expired - Fee Related
- 2002-10-23 NZ NZ532044A patent/NZ532044A/en unknown
- 2002-10-23 MX MXPA04003828A patent/MXPA04003828A/es active IP Right Grant
- 2002-10-23 EP EP02801961A patent/EP1450794A1/en not_active Withdrawn
- 2002-10-23 IL IL16119202A patent/IL161192A0/xx unknown
- 2002-10-23 CA CA002464256A patent/CA2464256A1/en not_active Abandoned
- 2002-10-23 US US10/491,288 patent/US7144886B2/en not_active Expired - Fee Related
- 2002-10-23 RU RU2004110055/04A patent/RU2004110055A/ru not_active Application Discontinuation
- 2002-10-23 PL PL02370149A patent/PL370149A1/xx not_active Application Discontinuation
- 2002-10-23 KR KR10-2004-7005917A patent/KR20040049321A/ko not_active Application Discontinuation
- 2002-10-23 HU HU0402403A patent/HUP0402403A3/hu unknown
- 2002-10-23 WO PCT/GB2002/004787 patent/WO2003035067A1/en not_active Application Discontinuation
-
2004
- 2004-03-30 ZA ZA200402500A patent/ZA200402500B/xx unknown
- 2004-05-19 NO NO20042114A patent/NO20042114L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA04003828A (es) | 2004-07-16 |
PL370149A1 (en) | 2005-05-16 |
KR20040049321A (ko) | 2004-06-11 |
US20050004205A1 (en) | 2005-01-06 |
AR037247A1 (es) | 2004-11-03 |
GB0125446D0 (en) | 2001-12-12 |
HUP0402403A3 (en) | 2009-05-28 |
US7144886B2 (en) | 2006-12-05 |
IL161192A0 (en) | 2004-08-31 |
NO20042114L (no) | 2004-07-21 |
JP2005510499A (ja) | 2005-04-21 |
CA2464256A1 (en) | 2003-05-01 |
NZ532044A (en) | 2005-03-24 |
ZA200402500B (en) | 2005-01-24 |
CN1575171A (zh) | 2005-02-02 |
HUP0402403A2 (hu) | 2005-04-28 |
CN1329375C (zh) | 2007-08-01 |
EP1450794A1 (en) | 2004-09-01 |
UY27511A1 (es) | 2003-04-30 |
WO2003035067A1 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004110055A (ru) | Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов | |
RU2001118826A (ru) | N-замещенные 2-цианопирролидины | |
RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
ATE433959T1 (de) | Analoge von kokain | |
RU2005108133A (ru) | Дипептиднитрильные ингибиторы катепсина к | |
RU99105119A (ru) | Производные пурина и их применение в качестве антикоагулянтов | |
RU94013439A (ru) | Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения | |
DK0405537T3 (da) | N-substituerede cycloalkyl og polycycloalkyl, alpha-substituerede Trp-Phe- og phenethylaminderivater | |
RU2003130058A (ru) | Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона | |
JP2004525179A5 (ru) | ||
JP2004505105A5 (ru) | ||
DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
CA2436846A1 (en) | Thioether substituted imidazoquinolines | |
EP1862458A3 (en) | Therapeutic agents useful for treating pain | |
JP2005511699A5 (ru) | ||
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
FI971951A0 (fi) | 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon | |
RU2004136853A (ru) | (s)-4-амино-5-хлор-2-метокси-n-[1-[1-(2-тетрагидрофурилкарбонил)-4- пиперидини лметил]-4-пиперидинил]бензамид, способ его получения, содержащая его фармацевтическая композиция и промежуточное соединение для его получения | |
KR960701007A (ko) | 피롤-아미딘계 화합물 및 약제학적으로 허용 가능한 그 염, 그 제조방법 및 상기 화합물을 포함하는 약제조성물 | |
EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
RU2000106042A (ru) | Способ повышения биологической доступности фексофенадина и его производных | |
ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
RU2005115102A (ru) | Новые противоопухолевые соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080326 |